Mount Sinai joins effort to develop COVID-19 hyperimmune globulin product candidate
The Mount Sinai Health System will partner with Emergent BioSolutions and ImmunoTek Bio Centers on the development and evaluation of a COVID-19 hyperimmune globulin product, it was announced yesterday. The COVID-HIG is prepared using convalescent plasma from COVID-19 patients to potentially prevent and treat the disease in the absence of a vaccine. The collaboration, which leverages $34.6 million in funding from the Department of Defense, includes a post-exposure prophylaxis study on health care providers at high risk of COVID-19 infection and other high-risk populations.
Related News Articles
Headline
The Department of Health and Human Services Dec. 10 amended the Public Readiness and Emergency Preparedness Act declaration for COVID-19, extending liability…
Headline
AHA's latest social media toolkit for encouraging vaccination against the flu and COVID-19 provides fall-themed social media posts and graphics. Download the…
Headline
The Centers for Disease Control and Prevention last week endorsed a recommendation for people aged 65 and older and for immunocompromised individuals to…
Headline
The Centers for Medicare & Medicaid Services Oct. 22 released final guidance detailing reporting requirements for the hospital respiratory data condition…
Headline
The Centers for Disease Control and Prevention is reminding clinicians and other health care workers to take necessary steps to keep themselves and their…
Headline
The National Institutes of Health Oct. 10 released results of a study that found that infection from COVID-19 in the first wave of the pandemic appeared to…